AKTX vs RTX · $17.2M cap vs P/E 36, rev $88.60B
Akari Therapeutics PLC (AKTX) versus RTX Corporation (RTX) — a side-by-side from cached financials, not a winner call.
Akari Therapeutics PLC (AKTX) is a biotechnology company listed on US.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
AKTX does not have a complete income-statement cache yet.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
AKTX currently screens at market cap $17.2M. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Not investment advice. Open the AKTX and RTX stock pages for the full models.
Not investment advice.